Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin

Adler-Mosca, H.; Lüthy-Hottenstein, J; Lucchini, Gladys Martinetti; Burnens, André P.; Altwegg, Martin

doi:10.1007/bf02005451

Cited by 59 publications

(30 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A kanamycin resistance determinant, aphA-3 was found located distal to Chromosomal: enzymatic modification of antibiotics. Integron-mediated resistance [113,175] Kanamycin Majority plasmid-borne, remainder chromosomal; resistance through enzymatic modification of kanamycin [140] Chloramphenicol Plasmid-borne, resistance through modification of the target site (ribosome) or alteration of the antibiotic [186] Ciprofloxacin Chromosomal: modification of gyrA and parC confers resistance [3,4,16] Erythromycin Chromosomally mediated, resistance through modification of the target site (ribosome) [166] β-Lactams Chromosomal; three mechanisms, decreased uptake through modification of a porin, alteration of a penicillin binding protein, or production of a β-lactamase [129] Tetracycline tetO gene, plasmid-borne in the majority of cases, resistance mediated through ribosomal protection [7,78,167] Trimethoprim dfr1 gene, chromosomal, located to the remnants of an integron dfr9 gene, chromosomal, located to the remnants of a transposon Resistance arising through modification of the trimethoprim target [53] Multidrug-resistance (MDR)…”

Section: Genetic Mechanisms Associatedmentioning

confidence: 99%

Campylobacter

et al. 2005

View full text Add to dashboard Cite

-Species within the genus, Campylobacter, have emerged over the last three decades as significant clinical pathogens, particularly of human public health concern, where the majority of acute bacterial enteritis in the Western world is due to these organisms. Of particular concern are the species, C. jejuni and C. coli, which are responsible for most of these gastrointestinal-related infections. Although these organisms have already emerged as causative agents of zoonoses, several aspects of their epidemiology and pathophysiology are only beginning to emerge. Trends in increasing antibiotic resistance are beginning to emerge with oral antibiotics, which may be the drug of choice for when it is necessary to intervene chemotherapeutically. This review wishes to examine (i) emerging clinical aspects of the disease, such as Guillain Barré syndrome (GBS), (ii) the association between these organisms and poultry as a natural host, (iii) environmental aspects of Campylobacter epidemiology, (iv) the emergence of atypical campylobacters (v) emerging trends in antibiotic resistance, (vi) adoption of modern methods for the detection of campylobacters.

show abstract

Section: Genetic Mechanisms Associatedmentioning

confidence: 99%

Campylobacter

et al. 2005

View full text Add to dashboard Cite

show abstract

“…appears to be selected by treatment of patients with these drugs (1). However, the development of fluoroquinolone resistance coincided not only with the extended usage of these drugs in humans but also with the introduction of fluoroquinolones into the raising of livestock (29).…”

mentioning

confidence: 99%

Susceptibilities of Campylobacter jejuni Isolates from Germany to Ciprofloxacin, Moxifloxacin, Erythromycin, Clindamycin, and Tetracycline

Wagner

Jabbusch

Eisenblätter

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

To elucidate Campylobacter jejuni resistance to antibiotics in Germany, MICs of ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline were determined (using agar dilution) for 144 clinical isolates. The data indicate a considerable ciprofloxacin resistance (45.1%) without a clonal relationship of the strains and a greater in vitro activity of moxifloxacin, erythromycin, and clindamycin.

show abstract

“…These drugs have been widely used to treat bacterial infections, including those due to Campylobacter jejuni and Campylobacter coli (1,8,26), which are a major cause of bacterial diarrhea in humans. High-level resistance to quinolones has been reported in Campylobacter spp.…”

mentioning

confidence: 99%

Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations

Wang

Huang

Taylor

1993

Antimicrob Agents Chemother

259

276

View full text Add to dashboard Cite

The gyrA gene of Campylobacterjejuni UA580, which encodes the A subunit of DNA gyrase, was cloned and its nucleotide sequence was determined. An open reading frame of 2,589 nucleotides was identified, which could code for a polypeptide of 863 amino acids with a Mr of 97 kDa. Both the nucleotide sequence and the putative amino acid sequence show ca. 50% identity with those of other gyrA genes from gram-positive and gram-negative bacteria. Similar mutations were also identified in ciprofloxacin-resistant isolates of S. aureus (10,27).Gootz and Martin (9) demonstrated that the DNA gyrases from Nalr mutants of C. jejuni UA535 were 100-fold less susceptible than the wild-type enzyme to inhibition by quinolones in the DNA supercoiling reaction. Subunit switching experiments with purified A and B subunits from the wild type and one of the quinolone-resistant mutants indicated that an alteration in the A subunit was responsible for resistance. Here, we report the cloning and nucleotide sequence of the C. jejuni gyrA gene and the location of the gene on both C. jejuni and C. coli chromosomes. Several mutations responsible for quinolone resistance were detected in the gyrA sequence. MATERUILS AND METHODSStrains and culture conditions. The Campylobacter spp. employed in this study were C. jejuni UA67 (Nalr mutant [35]); UA536, UA543, and UA549 (Nalr clinical isolates from H. Lior); UA580 (35); UA58OR1 and UA580R3 (Nalr mutant from UA580 [this study]); and C. coli UA417 (Nalr clinical isolates [35]). E. coli DH5at (23) was also used. The plasmids and phages employed were pUC19, M13mpl8, M13mpl9 (38), pBluescript II SK (Stratagene), pK194 (16), and pT7-5 (30).Campylobacters were grown at 37°C on Mueller-Hinton agar medium containing 7% CO2. E. coli was grown in 2x YT medium or on Luria-Bertani agar (23) at 37°C. When necessary, the medium was supplemented with ampicillin (100 ,ug/ml), kanamycin (15 jig/ml), or nalidixic acid (24 ig/ml).DNA isolation, transformation, and nucleotide sequence analysis. Plasmid DNA was isolated by a modification of the alkaline lysis method of Birnboim and Doly (2) and purified by the "magic miniprep" (Promega) when used for restriction analysis and sequencing. M13 phage DNA was prepared by the method described by Sambrook et al. (23).

show abstract

Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin

Cited by 59 publications

References 17 publications

Campylobacter

Campylobacter

Susceptibilities of Campylobacter jejuni Isolates from Germany to Ciprofloxacin, Moxifloxacin, Erythromycin, Clindamycin, and Tetracycline

Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations

Contact Info

Product

Resources

About